m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance

Tengfei Zhou,Shichao Li,Daimin Xiang,Junyu Liu,Wen Sun,Xiuliang Cui,Beifang Ning,Xiao Li,Zhuo Cheng,Weiqi Jiang,Cheng Zhang,Xijun Liang,Liang Li,Xin Cheng,Liu Hui,Hongyang Wang,Jin Ding

DOI: https://doi.org/10.1038/s41392-020-00299-0

IF: 39.3

2020-12-01

Signal Transduction and Targeted Therapy

Abstract:Abstract Hepatocyte nuclear factor 3γ (HNF3γ) is a hepatocyte nuclear factor, but its role and clinical significance in hepatocellular carcinoma (HCC) remain unclear. Herein, we report that HNF3γ expression is downregulated in patient HCC and inversely correlated with HCC malignancy and patient survival. Moreover, our data suggested that the HNF3γ reduction in HCC could be mediated by METTL14-dependent m6A methylation of HNF3γ mRNA. HNF3γ expression was increased during hepatic differentiation and decreased in dedifferentiated HCC cells. Interestingly, HNF3γ delivery promoted differentiation of not only HCC cells but also liver CSCs, which led to suppression of HCC growth. Mechanistic analysis suggested an HNF3γ-centered regulatory network that includes essential liver differentiation-associated transcription factors and functional molecules, which could synergistically facilitate HCC cell differentiation. More importantly, enforced HNF3γ expression sensitized HCC cells to sorafenib-induced growth inhibition and cell apoptosis through transactivation of OATP1B1 and OATP1B3 expression, which are major membrane transporters for sorafenib uptake. Clinical investigation showed that patient-derived HCC xenografts with high HNF3γ expression exhibited a sorafenib response and patients with high HCC HNF3γ levels benefited from sorafenib therapy. Together, these results suggest that HNF3γ plays an essential role in HCC differentiation and may serve as a therapeutic target and predictor of sorafenib benefit in patients.

biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The core problem that this paper attempts to solve is to explore the role of hepatocyte nuclear factor 3γ (HNF3γ) in hepatocellular carcinoma (HCC) and its relationship with patient prognosis, especially how the decreased expression of HNF3γ leads to HCC dedifferentiation and resistance to sorafenib treatment. Specifically, the researchers focused on the following aspects:

1. **Expression of HNF3γ in HCC**: The study found that the expression of HNF3γ in HCC tissues was significantly lower than that in normal liver tissues, and this decreased expression was negatively correlated with the malignancy of HCC and the survival rate of patients.

2. **Molecular mechanism of HNF3γ down - regulation**: Studies have shown that the down - regulation of HNF3γ expression may be caused by m6A RNA methylation mediated by m6A methyltransferase METTL14. The decrease in METTL14 levels is related to the reduction in HNF3γ expression, which may be a key factor in the decrease in HNF3γ expression in HCC.

3. **Role of HNF3γ in HCC differentiation**: Through in vitro experiments, the researchers found that over - expression of HNF3γ can promote the differentiation of HCC cells and liver cancer stem cells, thereby inhibiting the growth of HCC.

4. **Relationship between HNF3γ and sorafenib treatment response**: The study further revealed that HNF3γ can enhance the sensitivity of HCC cells to sorafenib by up - regulating the expression of OATP1B1 and OATP1B3. These two proteins are the main membrane transporters responsible for sorafenib uptake.

In summary, this paper aims to clarify the important role of HNF3γ in HCC progression, especially its impact on tumor dedifferentiation and drug tolerance, as well as its potential as a potential treatment target and a marker for predicting the efficacy of sorafenib.